Oncology Institute, Inc. 8-K

What Happened
On January 12, 2026, The Oncology Institute, Inc. filed a Form 8‑K (Item 2.02) and issued a press release reaffirming the company’s 2025 financial guidance and providing a preliminary financial outlook for 2026 along with certain longer‑term guidance. The press release was furnished as Exhibit 99.1 to the 8‑K and is incorporated by reference.

Key Details

• Filing date: January 12, 2026 (Form 8‑K, Item 2.02 — Results of Operations and Financial Condition).
• Company action: Reaffirmed 2025 financial guidance.
• Forward information: Provided preliminary 2026 financial outlook and additional longer‑term guidance.
• Disclosure format: Press release furnished as Exhibit 99.1 to the 8‑K.

Why It Matters
Guidance and outlook are primary inputs for analysts’ earnings models and investor expectations of future revenue and profitability. Reaffirmation of 2025 guidance signals management expects to meet prior targets, while a preliminary 2026 outlook and longer‑term guidance give investors new forward‑looking information to update forecasts and assess the company’s growth trajectory. Investors should review the Exhibit 99.1 press release for the specific financial figures and monitor subsequent SEC filings and earnings reports for finalized results.